13558-76-4

Basic information

• Product Name: 1-(2-chloroacetyl)-3-o-tolylurea
• Synonyms: 1-(2-chloroacetyl)-3-o-tolylurea
• CAS NO: 13558-76-4
• Molecular Formula: C₁₀H₁₁ClN₂O₂
• Molecular Weight: 226.65954
• Mol File: 13558-76-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 135-137 °C
• Appearance: /
• Density: 1.313±0.06 g/cm3(Predicted)
• PKA: 10.04±0.70(Predicted)
• CAS DataBase Reference: 1-(2-chloroacetyl)-3-o-tolylurea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroacetyl)-3-o-tolylurea(13558-76-4)
• EPA Substance Registry System: 1-(2-chloroacetyl)-3-o-tolylurea(13558-76-4)

Safety Data

• Hazardous Substances Data: 13558-76-4(Hazardous Substances Data)

Usage

General Description

1-(2-chloroacetyl)-3-o-tolylurea is a chemical compound that is commonly used in the synthesis of pharmaceuticals and other organic compounds. It is a urea derivative with a molecular formula of C10H11ClN2O2 and a molecular weight of 228.66 g/mol. 1-(2-chloroacetyl)-3-o-tolylurea is known for its antifungal and antibacterial properties, making it an important ingredient in certain medications. It is also used in the production of herbicides and pesticides. 1-(2-chloroacetyl)-3-o-tolylurea is typically a white to off-white crystalline powder that is soluble in organic solvents such as acetone and methanol. It is important to handle this chemical with caution and adhere to proper safety protocols when working with it.

Upstream product

• 79-37-8 oxalyl dichloride 
• 95-53-4 o-toluidine 
• 79-07-2 Chloroacetamide 
• 471-46-5 Oxalamide 
• 614-77-7 N-(2-methylphenyl)urea 
• 79-04-9 chloroacetyl chloride 
• 4461-30-7 2-chloroacetylisocyanate 

Downstream Products

• 86538-77-4 2-(1H-benzoimidazol-2-ylsulfanyl)-N-o-tolylcarbamoyl-acetamide 
• 76427-06-0 1-(2-{N'-[1-(4-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-acetyl)-3-o-tolyl-urea 
• 76427-07-1 1-(2-{N'-[1-(4-Hydroxy-3-methoxy-phenyl)-meth-(E)-ylidene]-hydrazino}-acetyl)-3-o-tolyl-urea 
• 76427-05-9 1-(2-{N'-[1-(2-Hydroxy-phenyl)-meth-(E)-ylidene]-hydrazino}-acetyl)-3-o-tolyl-urea 
• 76427-04-8 1-o-Tolyl-3-(2-{N'-[1-p-tolyl-meth-(E)-ylidene]-hydrazino}-acetyl)-urea 
• 76427-03-7 1-(2-{N'-[1-Phenyl-meth-(E)-ylidene]-hydrazino}-acetyl)-3-o-tolyl-urea 
• 76427-47-9 1-(2-Hydrazino-acetyl)-3-o-tolyl-urea 
• 76979-61-8 1-{2-[(6-Nitro-4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-3-o-tolyl-urea 
• 83315-89-3 1-{2-[6,8-Dibromo-3-(3-methoxy-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-ylsulfanyl]-acetyl}-3-o-tolyl-urea 
• 97399-35-4 1-{2-[5-(3,5-Dibromo-2-hydroxy-phenyl)-4-p-tolyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetyl}-3-o-tolyl-urea 

Relevant articles and documents

Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety

Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.

Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40–Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4.

Synthesis and evaluation of substituted 4(3H)-quinazolone derivatives for antimicrobial and antiacetylcholinesterase activities. Part 3

-